VEGF-165 serum levels and tyrosinase expression in melanoma patients: Correlation with the clinical course

Melanoma Research

Volumn 12, Issue 4, 2002, Pages 325-334

  Osella Abate, S ^a   Quaglino, P ^a   Savoia, P ^a   Leporati, C ^a   Comessatti, A ^a   Bernengo, Maria Grazia ^a  

^a Second Dermatologic Clinic   (Italy)

Author keywords

Angiogenesis; ELISA; Melanoma progression; Metastatic melanoma; Multivariate analysis; Tyrosinase; VEGF

Indexed keywords

MESSENGER RNA; MONOPHENOL MONOOXYGENASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; RNA; SIGNAL PEPTIDE; TUMOR MARKER; TUMOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BLOOD; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ENZYMOLOGY; EVALUATION; LIFE TABLE; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SURVIVAL; TUMOR EMBOLISM;

ADULT; AGED; COHORT STUDIES; COMPARATIVE STUDY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; FOLLOW-UP STUDIES; HUMAN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIFE TABLES; LYMPHOKINES; MALE; MELANOMA; MIDDLE AGE; MONOPHENOL MONOOXYGENASE; MULTIVARIATE ANALYSIS; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; HUMANS; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036021004     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200208000-00004     Document Type: Article

References (51)

1. What is the evidence that tumors are angiogenesis dependent?
2. The vascular endothelial growth factor family of polypeptides
3. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
4. VEGF 121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells
5. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors
6. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
7. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
8. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma
9. Expression of vascular endothelial growth factor and its receptor fit and KDR in ovarian carcinoma
10. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor
11. Vascular permeability factor, tumor angiogenesis and stroma generation
12. Concentration of vascular endothelial growth factor in sera of normal control and cancer patients
13. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
14. Serum vascular endothelial growth factor is often elevated in disseminated cancer
15. Clinical implications of circulating angiogenic factors in cancer patients
16. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis
17. Peripheral blood T lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis
18. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
19. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma
20. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
21. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma
22. Role of RT-PCR tyrosinase detection in the monitoring of patients with advanced metastatic melanoma
23. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors
24. Tumour microdissemination and survival in metastatic melanoma
25. A new American Joint Committee on Cancer staging system for cutaneous melanoma
26. Studies of interferons in the therapy of melanoma
27. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
28. Reporting results of cancer treatment
29. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
30. Non-parametric estimation from incomplete observations
31. Evaluation of survival data and two new rank order statistics arising in its consideration
32. Regression models as life-tables
33. Recurrent malignant melanoma: The identification of prognostic factors to predict survival
34. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis
35. An improved and combined reverse transcription-polymerase chain reaction assay for reliable detection of metastatic melanoma cells in peripheral blood
36. Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment and recurrence from melanoma
37. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: Evaluation strategy and correlation with known prognostic markers in 123 melanoma patients
38. Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients
39. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma
40. Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR
41. Tumor vascularity as a prognostic indicator in intermediate-thickness (0.76-4 mm) cutaneous melanoma. A quantitative assay
42. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin
43. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma
44. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
45. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
46. Chemotherapy and angiogenesis in advanced cancer: Vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer
47. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells
48. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids
49. Macrophages and angiogenesis
50. Platelet: Transporter of vascular endothelial growth factor
51. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets